Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

eUpdate – Testicular Seminoma and Non-Seminoma Treatment Recommendations

eUpdate – Testicular Seminoma and Non-Seminoma Treatment Recommendations

Published: 29 June 2017. Authors: Oldenburg J and Horwich A, on behalf of the ESMO Guidelines Committee

Clinical Practice Guidelines

This update refers to the Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Oldenburg J, Fosså SD, Nuver J et al, Ann Oncol 2016; 24 (Suppl 6): vi125–vi132.

Section

Post-orchiectomy staging and risk assessment

Text update

A new third paragraph is added: In summary, stage I tumours appear to be confined to the testis (although those in stage I with rising post-orchidectomy markers are accepted to have subclinical metastatic disease). Stage II tumours have abdominal node metastases IIA < 2 cm diameter, IIB 2–5 cm and IIC > 5 cm) and stage III tumours have more widespread metastases. Serum tumour marker (S) levels for prognostication of metastatic non-seminomas are classified into three groups, as follows:

  • All the markers must be in the stated range to be considered S1;
  • Only one marker needs to be in the stated range to be considered S2 or S3.

Section

Tables 1–5.

Text update

This eUpdate provides a new Table 1 and a new Table 2 to replace the original Table 1. ‘Post-orchiectomy staging of metastatic seminoma and non-seminoma according to AJCC/UICC and IGCCCG classification.’ Original Tables 2–4 are now Tables 3–5.

Serum tumour markers for non-seminoma testicular cancer

---

LDH (U/L)

HCG (IU/L)

AFP (ng/mL)

SX

Marker studies not available or not carried out

Marker studies not available or not carried out

Marker studies not available or not carried out

S0

Normal

Normal

Normal

S1

< 1.5x ULN

< 5000

< 1000

S2

1.5–10x ULN

5000–50 000

1000–10 000

S3

> 10x ULN

> 50 000

> 10 000

AFP, alpha-fetoprotein; hCG, human chorionic gonadotropin; LDH, lactate dehydrogenase; ULN, upper limit of normal.

The IGCCCG Prognostic Classification for metastatic germ cell cancers

Good-prognosis group

Non-seminoma (56% of cases)

All of the following criteria:

5-year PFS 89%
5-year survival 92%

  • Testicular/retroperitoneal primary
  • No non-pulmonary visceral metastases
  • AFP < 1000 ng/mL
  • hCG < 5000 IU/L (1000 ng/mL)
  • LDH < 1.5x ULN

Seminoma (90% of cases)

All of the following criteria:

5-year PFS 82%
5-year survival 86%

  • Any primary site
  • No non-pulmonary visceral metastases
  • Normal AFP
  • Any hCG
  • Any LDH

Intermediate prognosis group

Non-seminoma (28% of cases)

---

5-year PFS 75%

  • Testicular/retroperitoneal primary
  • No non-pulmonary visceral metastases

5-year survival 80%

And any of the following criteria:
hCG 5000–50 000 IU/L or
LDH 1.5–10x ULN

Seminoma (10% of cases)

All of the following criteria:

5-year PFS 67%
5-year survival 72%

  • Any primary site
  • Non-pulmonary visceral metastases
  • Normal AFP
  • Any hCG
  • Any LDH

Poor prognosis group

Non-seminoma (16% of cases)

Any of the following criteria:

5-year PFS 41%
5-year survival 48%

  • Mediastinal primary
  • Non-pulmonary visceral metastases
  • AFP > 10 000 ng/mL or
  • hCG > 50 000 IU/L (10 000 ng/mL) or
  • LDH > 10x ULN

Seminoma

No patients classified as poor prognosis

Pre-chemotherapy serum tumour markers should be assessed after orchiectomy and immediately prior to the administration of chemotherapy (same day).

AFP, alpha-fetoprotein; hCG, human chorionic gonadotropin; IGCCCG, International Germ Cell Cancer Collaborative Group; LDH, lactate dehydrogenase; PFS, progression-free survival; ULN, upper limit of normal.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings